Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials
Abstract Reliable and responsive tools for monitoring disease activity and treatment outcomes in patients with neuropathies are lacking. With the emergence of ultrasensitive blood bioassays, proteins released with nerve damage are potentially useful response biomarkers for many neurological disorder...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Wieske, Luuk [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2021 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© The Author(s) 2021. corrected publication 2021 |
|---|
| Übergeordnetes Werk: |
Enthalten in: NeuroRX - Springer-Verlag, 2006, 18(2021), 4 vom: Okt., Seite 2351-2367 |
|---|---|
| Übergeordnetes Werk: |
volume:18 ; year:2021 ; number:4 ; month:10 ; pages:2351-2367 |
| Links: |
|---|
| DOI / URN: |
10.1007/s13311-021-01136-0 |
|---|
| Katalog-ID: |
SPR046114831 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR046114831 | ||
| 003 | DE-627 | ||
| 005 | 20230519182915.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220201s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13311-021-01136-0 |2 doi | |
| 035 | |a (DE-627)SPR046114831 | ||
| 035 | |a (SPR)s13311-021-01136-0-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wieske, Luuk |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2021. corrected publication 2021 | ||
| 520 | |a Abstract Reliable and responsive tools for monitoring disease activity and treatment outcomes in patients with neuropathies are lacking. With the emergence of ultrasensitive blood bioassays, proteins released with nerve damage are potentially useful response biomarkers for many neurological disorders, including polyneuropathies. In this review, we provide an overview of the existing literature focusing on potential applications in polyneuropathy clinical care and trials. Whilst several promising candidates have been identified, no studies have investigated if any of these proteins can serve as response biomarkers of longitudinal disease activity, except for neurofilament light (NfL). For NfL, limited evidence exists supporting a role as a response biomarker in Guillain-Barré syndrome, vasculitic neuropathy, and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Most evidence exists for NfL as a response biomarker in hereditary transthyretin-related amyloidosis (hATTR). At the present time, the role of NfL is therefore limited to a supporting clinical tool or exploratory endpoint in trials. Future developments will need to focus on the discovery of additional biomarkers for anatomically specific and other forms of nerve damage using high-throughput technologies and highly sensitive analytical platforms in adequality powered studies of appropriate design. For NfL, a better understanding of cut-off values, the relation to clinical symptoms and long-term disability as well as dynamics in serum on and off treatment is needed to further expand and proceed towards implementation. | ||
| 650 | 4 | |a Biomarkers |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Nerve damage |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Polyneuropathies |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Neurofilament light chain |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Smyth, Duncan |4 aut | |
| 700 | 1 | |a Lunn, Michael P. |4 aut | |
| 700 | 1 | |a Eftimov, Filip |4 aut | |
| 700 | 1 | |a Teunissen, Charlotte E. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t NeuroRX |d Springer-Verlag, 2006 |g 18(2021), 4 vom: Okt., Seite 2351-2367 |w (DE-627)SPR031264964 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2021 |g number:4 |g month:10 |g pages:2351-2367 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13311-021-01136-0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2021 |e 4 |c 10 |h 2351-2367 | ||
| author_variant |
l w lw d s ds m p l mp mpl f e fe c e t ce cet |
|---|---|
| matchkey_str |
wieskeluuksmythduncanlunnmichaelpeftimov:2021----:liboakrfroioigtutrlhneiplnuoahetersi |
| hierarchy_sort_str |
2021 |
| publishDate |
2021 |
| allfields |
10.1007/s13311-021-01136-0 doi (DE-627)SPR046114831 (SPR)s13311-021-01136-0-e DE-627 ger DE-627 rakwb eng Wieske, Luuk verfasserin aut Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2021. corrected publication 2021 Abstract Reliable and responsive tools for monitoring disease activity and treatment outcomes in patients with neuropathies are lacking. With the emergence of ultrasensitive blood bioassays, proteins released with nerve damage are potentially useful response biomarkers for many neurological disorders, including polyneuropathies. In this review, we provide an overview of the existing literature focusing on potential applications in polyneuropathy clinical care and trials. Whilst several promising candidates have been identified, no studies have investigated if any of these proteins can serve as response biomarkers of longitudinal disease activity, except for neurofilament light (NfL). For NfL, limited evidence exists supporting a role as a response biomarker in Guillain-Barré syndrome, vasculitic neuropathy, and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Most evidence exists for NfL as a response biomarker in hereditary transthyretin-related amyloidosis (hATTR). At the present time, the role of NfL is therefore limited to a supporting clinical tool or exploratory endpoint in trials. Future developments will need to focus on the discovery of additional biomarkers for anatomically specific and other forms of nerve damage using high-throughput technologies and highly sensitive analytical platforms in adequality powered studies of appropriate design. For NfL, a better understanding of cut-off values, the relation to clinical symptoms and long-term disability as well as dynamics in serum on and off treatment is needed to further expand and proceed towards implementation. Biomarkers (dpeaa)DE-He213 Nerve damage (dpeaa)DE-He213 Polyneuropathies (dpeaa)DE-He213 Neurofilament light chain (dpeaa)DE-He213 Smyth, Duncan aut Lunn, Michael P. aut Eftimov, Filip aut Teunissen, Charlotte E. aut Enthalten in NeuroRX Springer-Verlag, 2006 18(2021), 4 vom: Okt., Seite 2351-2367 (DE-627)SPR031264964 nnns volume:18 year:2021 number:4 month:10 pages:2351-2367 https://dx.doi.org/10.1007/s13311-021-01136-0 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 18 2021 4 10 2351-2367 |
| spelling |
10.1007/s13311-021-01136-0 doi (DE-627)SPR046114831 (SPR)s13311-021-01136-0-e DE-627 ger DE-627 rakwb eng Wieske, Luuk verfasserin aut Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2021. corrected publication 2021 Abstract Reliable and responsive tools for monitoring disease activity and treatment outcomes in patients with neuropathies are lacking. With the emergence of ultrasensitive blood bioassays, proteins released with nerve damage are potentially useful response biomarkers for many neurological disorders, including polyneuropathies. In this review, we provide an overview of the existing literature focusing on potential applications in polyneuropathy clinical care and trials. Whilst several promising candidates have been identified, no studies have investigated if any of these proteins can serve as response biomarkers of longitudinal disease activity, except for neurofilament light (NfL). For NfL, limited evidence exists supporting a role as a response biomarker in Guillain-Barré syndrome, vasculitic neuropathy, and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Most evidence exists for NfL as a response biomarker in hereditary transthyretin-related amyloidosis (hATTR). At the present time, the role of NfL is therefore limited to a supporting clinical tool or exploratory endpoint in trials. Future developments will need to focus on the discovery of additional biomarkers for anatomically specific and other forms of nerve damage using high-throughput technologies and highly sensitive analytical platforms in adequality powered studies of appropriate design. For NfL, a better understanding of cut-off values, the relation to clinical symptoms and long-term disability as well as dynamics in serum on and off treatment is needed to further expand and proceed towards implementation. Biomarkers (dpeaa)DE-He213 Nerve damage (dpeaa)DE-He213 Polyneuropathies (dpeaa)DE-He213 Neurofilament light chain (dpeaa)DE-He213 Smyth, Duncan aut Lunn, Michael P. aut Eftimov, Filip aut Teunissen, Charlotte E. aut Enthalten in NeuroRX Springer-Verlag, 2006 18(2021), 4 vom: Okt., Seite 2351-2367 (DE-627)SPR031264964 nnns volume:18 year:2021 number:4 month:10 pages:2351-2367 https://dx.doi.org/10.1007/s13311-021-01136-0 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 18 2021 4 10 2351-2367 |
| allfields_unstemmed |
10.1007/s13311-021-01136-0 doi (DE-627)SPR046114831 (SPR)s13311-021-01136-0-e DE-627 ger DE-627 rakwb eng Wieske, Luuk verfasserin aut Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2021. corrected publication 2021 Abstract Reliable and responsive tools for monitoring disease activity and treatment outcomes in patients with neuropathies are lacking. With the emergence of ultrasensitive blood bioassays, proteins released with nerve damage are potentially useful response biomarkers for many neurological disorders, including polyneuropathies. In this review, we provide an overview of the existing literature focusing on potential applications in polyneuropathy clinical care and trials. Whilst several promising candidates have been identified, no studies have investigated if any of these proteins can serve as response biomarkers of longitudinal disease activity, except for neurofilament light (NfL). For NfL, limited evidence exists supporting a role as a response biomarker in Guillain-Barré syndrome, vasculitic neuropathy, and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Most evidence exists for NfL as a response biomarker in hereditary transthyretin-related amyloidosis (hATTR). At the present time, the role of NfL is therefore limited to a supporting clinical tool or exploratory endpoint in trials. Future developments will need to focus on the discovery of additional biomarkers for anatomically specific and other forms of nerve damage using high-throughput technologies and highly sensitive analytical platforms in adequality powered studies of appropriate design. For NfL, a better understanding of cut-off values, the relation to clinical symptoms and long-term disability as well as dynamics in serum on and off treatment is needed to further expand and proceed towards implementation. Biomarkers (dpeaa)DE-He213 Nerve damage (dpeaa)DE-He213 Polyneuropathies (dpeaa)DE-He213 Neurofilament light chain (dpeaa)DE-He213 Smyth, Duncan aut Lunn, Michael P. aut Eftimov, Filip aut Teunissen, Charlotte E. aut Enthalten in NeuroRX Springer-Verlag, 2006 18(2021), 4 vom: Okt., Seite 2351-2367 (DE-627)SPR031264964 nnns volume:18 year:2021 number:4 month:10 pages:2351-2367 https://dx.doi.org/10.1007/s13311-021-01136-0 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 18 2021 4 10 2351-2367 |
| allfieldsGer |
10.1007/s13311-021-01136-0 doi (DE-627)SPR046114831 (SPR)s13311-021-01136-0-e DE-627 ger DE-627 rakwb eng Wieske, Luuk verfasserin aut Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2021. corrected publication 2021 Abstract Reliable and responsive tools for monitoring disease activity and treatment outcomes in patients with neuropathies are lacking. With the emergence of ultrasensitive blood bioassays, proteins released with nerve damage are potentially useful response biomarkers for many neurological disorders, including polyneuropathies. In this review, we provide an overview of the existing literature focusing on potential applications in polyneuropathy clinical care and trials. Whilst several promising candidates have been identified, no studies have investigated if any of these proteins can serve as response biomarkers of longitudinal disease activity, except for neurofilament light (NfL). For NfL, limited evidence exists supporting a role as a response biomarker in Guillain-Barré syndrome, vasculitic neuropathy, and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Most evidence exists for NfL as a response biomarker in hereditary transthyretin-related amyloidosis (hATTR). At the present time, the role of NfL is therefore limited to a supporting clinical tool or exploratory endpoint in trials. Future developments will need to focus on the discovery of additional biomarkers for anatomically specific and other forms of nerve damage using high-throughput technologies and highly sensitive analytical platforms in adequality powered studies of appropriate design. For NfL, a better understanding of cut-off values, the relation to clinical symptoms and long-term disability as well as dynamics in serum on and off treatment is needed to further expand and proceed towards implementation. Biomarkers (dpeaa)DE-He213 Nerve damage (dpeaa)DE-He213 Polyneuropathies (dpeaa)DE-He213 Neurofilament light chain (dpeaa)DE-He213 Smyth, Duncan aut Lunn, Michael P. aut Eftimov, Filip aut Teunissen, Charlotte E. aut Enthalten in NeuroRX Springer-Verlag, 2006 18(2021), 4 vom: Okt., Seite 2351-2367 (DE-627)SPR031264964 nnns volume:18 year:2021 number:4 month:10 pages:2351-2367 https://dx.doi.org/10.1007/s13311-021-01136-0 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 18 2021 4 10 2351-2367 |
| allfieldsSound |
10.1007/s13311-021-01136-0 doi (DE-627)SPR046114831 (SPR)s13311-021-01136-0-e DE-627 ger DE-627 rakwb eng Wieske, Luuk verfasserin aut Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2021. corrected publication 2021 Abstract Reliable and responsive tools for monitoring disease activity and treatment outcomes in patients with neuropathies are lacking. With the emergence of ultrasensitive blood bioassays, proteins released with nerve damage are potentially useful response biomarkers for many neurological disorders, including polyneuropathies. In this review, we provide an overview of the existing literature focusing on potential applications in polyneuropathy clinical care and trials. Whilst several promising candidates have been identified, no studies have investigated if any of these proteins can serve as response biomarkers of longitudinal disease activity, except for neurofilament light (NfL). For NfL, limited evidence exists supporting a role as a response biomarker in Guillain-Barré syndrome, vasculitic neuropathy, and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Most evidence exists for NfL as a response biomarker in hereditary transthyretin-related amyloidosis (hATTR). At the present time, the role of NfL is therefore limited to a supporting clinical tool or exploratory endpoint in trials. Future developments will need to focus on the discovery of additional biomarkers for anatomically specific and other forms of nerve damage using high-throughput technologies and highly sensitive analytical platforms in adequality powered studies of appropriate design. For NfL, a better understanding of cut-off values, the relation to clinical symptoms and long-term disability as well as dynamics in serum on and off treatment is needed to further expand and proceed towards implementation. Biomarkers (dpeaa)DE-He213 Nerve damage (dpeaa)DE-He213 Polyneuropathies (dpeaa)DE-He213 Neurofilament light chain (dpeaa)DE-He213 Smyth, Duncan aut Lunn, Michael P. aut Eftimov, Filip aut Teunissen, Charlotte E. aut Enthalten in NeuroRX Springer-Verlag, 2006 18(2021), 4 vom: Okt., Seite 2351-2367 (DE-627)SPR031264964 nnns volume:18 year:2021 number:4 month:10 pages:2351-2367 https://dx.doi.org/10.1007/s13311-021-01136-0 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 18 2021 4 10 2351-2367 |
| language |
English |
| source |
Enthalten in NeuroRX 18(2021), 4 vom: Okt., Seite 2351-2367 volume:18 year:2021 number:4 month:10 pages:2351-2367 |
| sourceStr |
Enthalten in NeuroRX 18(2021), 4 vom: Okt., Seite 2351-2367 volume:18 year:2021 number:4 month:10 pages:2351-2367 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Biomarkers Nerve damage Polyneuropathies Neurofilament light chain |
| isfreeaccess_bool |
true |
| container_title |
NeuroRX |
| authorswithroles_txt_mv |
Wieske, Luuk @@aut@@ Smyth, Duncan @@aut@@ Lunn, Michael P. @@aut@@ Eftimov, Filip @@aut@@ Teunissen, Charlotte E. @@aut@@ |
| publishDateDaySort_date |
2021-10-01T00:00:00Z |
| hierarchy_top_id |
SPR031264964 |
| id |
SPR046114831 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR046114831</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519182915.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220201s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13311-021-01136-0</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR046114831</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13311-021-01136-0-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Wieske, Luuk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2021. corrected publication 2021</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Reliable and responsive tools for monitoring disease activity and treatment outcomes in patients with neuropathies are lacking. With the emergence of ultrasensitive blood bioassays, proteins released with nerve damage are potentially useful response biomarkers for many neurological disorders, including polyneuropathies. In this review, we provide an overview of the existing literature focusing on potential applications in polyneuropathy clinical care and trials. Whilst several promising candidates have been identified, no studies have investigated if any of these proteins can serve as response biomarkers of longitudinal disease activity, except for neurofilament light (NfL). For NfL, limited evidence exists supporting a role as a response biomarker in Guillain-Barré syndrome, vasculitic neuropathy, and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Most evidence exists for NfL as a response biomarker in hereditary transthyretin-related amyloidosis (hATTR). At the present time, the role of NfL is therefore limited to a supporting clinical tool or exploratory endpoint in trials. Future developments will need to focus on the discovery of additional biomarkers for anatomically specific and other forms of nerve damage using high-throughput technologies and highly sensitive analytical platforms in adequality powered studies of appropriate design. For NfL, a better understanding of cut-off values, the relation to clinical symptoms and long-term disability as well as dynamics in serum on and off treatment is needed to further expand and proceed towards implementation.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biomarkers</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nerve damage</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Polyneuropathies</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neurofilament light chain</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Smyth, Duncan</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lunn, Michael P.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Eftimov, Filip</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Teunissen, Charlotte E.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">NeuroRX</subfield><subfield code="d">Springer-Verlag, 2006</subfield><subfield code="g">18(2021), 4 vom: Okt., Seite 2351-2367</subfield><subfield code="w">(DE-627)SPR031264964</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:18</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:4</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:2351-2367</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13311-021-01136-0</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">18</subfield><subfield code="j">2021</subfield><subfield code="e">4</subfield><subfield code="c">10</subfield><subfield code="h">2351-2367</subfield></datafield></record></collection>
|
| author |
Wieske, Luuk |
| spellingShingle |
Wieske, Luuk misc Biomarkers misc Nerve damage misc Polyneuropathies misc Neurofilament light chain Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials |
| authorStr |
Wieske, Luuk |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)SPR031264964 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials Biomarkers (dpeaa)DE-He213 Nerve damage (dpeaa)DE-He213 Polyneuropathies (dpeaa)DE-He213 Neurofilament light chain (dpeaa)DE-He213 |
| topic |
misc Biomarkers misc Nerve damage misc Polyneuropathies misc Neurofilament light chain |
| topic_unstemmed |
misc Biomarkers misc Nerve damage misc Polyneuropathies misc Neurofilament light chain |
| topic_browse |
misc Biomarkers misc Nerve damage misc Polyneuropathies misc Neurofilament light chain |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
NeuroRX |
| hierarchy_parent_id |
SPR031264964 |
| hierarchy_top_title |
NeuroRX |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)SPR031264964 |
| title |
Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials |
| ctrlnum |
(DE-627)SPR046114831 (SPR)s13311-021-01136-0-e |
| title_full |
Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials |
| author_sort |
Wieske, Luuk |
| journal |
NeuroRX |
| journalStr |
NeuroRX |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
txt |
| container_start_page |
2351 |
| author_browse |
Wieske, Luuk Smyth, Duncan Lunn, Michael P. Eftimov, Filip Teunissen, Charlotte E. |
| container_volume |
18 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Wieske, Luuk |
| doi_str_mv |
10.1007/s13311-021-01136-0 |
| title_sort |
fluid biomarkers for monitoring structural changes in polyneuropathies: their use in clinical practice and trials |
| title_auth |
Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials |
| abstract |
Abstract Reliable and responsive tools for monitoring disease activity and treatment outcomes in patients with neuropathies are lacking. With the emergence of ultrasensitive blood bioassays, proteins released with nerve damage are potentially useful response biomarkers for many neurological disorders, including polyneuropathies. In this review, we provide an overview of the existing literature focusing on potential applications in polyneuropathy clinical care and trials. Whilst several promising candidates have been identified, no studies have investigated if any of these proteins can serve as response biomarkers of longitudinal disease activity, except for neurofilament light (NfL). For NfL, limited evidence exists supporting a role as a response biomarker in Guillain-Barré syndrome, vasculitic neuropathy, and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Most evidence exists for NfL as a response biomarker in hereditary transthyretin-related amyloidosis (hATTR). At the present time, the role of NfL is therefore limited to a supporting clinical tool or exploratory endpoint in trials. Future developments will need to focus on the discovery of additional biomarkers for anatomically specific and other forms of nerve damage using high-throughput technologies and highly sensitive analytical platforms in adequality powered studies of appropriate design. For NfL, a better understanding of cut-off values, the relation to clinical symptoms and long-term disability as well as dynamics in serum on and off treatment is needed to further expand and proceed towards implementation. © The Author(s) 2021. corrected publication 2021 |
| abstractGer |
Abstract Reliable and responsive tools for monitoring disease activity and treatment outcomes in patients with neuropathies are lacking. With the emergence of ultrasensitive blood bioassays, proteins released with nerve damage are potentially useful response biomarkers for many neurological disorders, including polyneuropathies. In this review, we provide an overview of the existing literature focusing on potential applications in polyneuropathy clinical care and trials. Whilst several promising candidates have been identified, no studies have investigated if any of these proteins can serve as response biomarkers of longitudinal disease activity, except for neurofilament light (NfL). For NfL, limited evidence exists supporting a role as a response biomarker in Guillain-Barré syndrome, vasculitic neuropathy, and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Most evidence exists for NfL as a response biomarker in hereditary transthyretin-related amyloidosis (hATTR). At the present time, the role of NfL is therefore limited to a supporting clinical tool or exploratory endpoint in trials. Future developments will need to focus on the discovery of additional biomarkers for anatomically specific and other forms of nerve damage using high-throughput technologies and highly sensitive analytical platforms in adequality powered studies of appropriate design. For NfL, a better understanding of cut-off values, the relation to clinical symptoms and long-term disability as well as dynamics in serum on and off treatment is needed to further expand and proceed towards implementation. © The Author(s) 2021. corrected publication 2021 |
| abstract_unstemmed |
Abstract Reliable and responsive tools for monitoring disease activity and treatment outcomes in patients with neuropathies are lacking. With the emergence of ultrasensitive blood bioassays, proteins released with nerve damage are potentially useful response biomarkers for many neurological disorders, including polyneuropathies. In this review, we provide an overview of the existing literature focusing on potential applications in polyneuropathy clinical care and trials. Whilst several promising candidates have been identified, no studies have investigated if any of these proteins can serve as response biomarkers of longitudinal disease activity, except for neurofilament light (NfL). For NfL, limited evidence exists supporting a role as a response biomarker in Guillain-Barré syndrome, vasculitic neuropathy, and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Most evidence exists for NfL as a response biomarker in hereditary transthyretin-related amyloidosis (hATTR). At the present time, the role of NfL is therefore limited to a supporting clinical tool or exploratory endpoint in trials. Future developments will need to focus on the discovery of additional biomarkers for anatomically specific and other forms of nerve damage using high-throughput technologies and highly sensitive analytical platforms in adequality powered studies of appropriate design. For NfL, a better understanding of cut-off values, the relation to clinical symptoms and long-term disability as well as dynamics in serum on and off treatment is needed to further expand and proceed towards implementation. © The Author(s) 2021. corrected publication 2021 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA |
| container_issue |
4 |
| title_short |
Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials |
| url |
https://dx.doi.org/10.1007/s13311-021-01136-0 |
| remote_bool |
true |
| author2 |
Smyth, Duncan Lunn, Michael P. Eftimov, Filip Teunissen, Charlotte E. |
| author2Str |
Smyth, Duncan Lunn, Michael P. Eftimov, Filip Teunissen, Charlotte E. |
| ppnlink |
SPR031264964 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s13311-021-01136-0 |
| up_date |
2024-07-03T20:27:41.990Z |
| _version_ |
1803591050320674816 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR046114831</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519182915.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220201s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13311-021-01136-0</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR046114831</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13311-021-01136-0-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Wieske, Luuk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2021. corrected publication 2021</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Reliable and responsive tools for monitoring disease activity and treatment outcomes in patients with neuropathies are lacking. With the emergence of ultrasensitive blood bioassays, proteins released with nerve damage are potentially useful response biomarkers for many neurological disorders, including polyneuropathies. In this review, we provide an overview of the existing literature focusing on potential applications in polyneuropathy clinical care and trials. Whilst several promising candidates have been identified, no studies have investigated if any of these proteins can serve as response biomarkers of longitudinal disease activity, except for neurofilament light (NfL). For NfL, limited evidence exists supporting a role as a response biomarker in Guillain-Barré syndrome, vasculitic neuropathy, and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Most evidence exists for NfL as a response biomarker in hereditary transthyretin-related amyloidosis (hATTR). At the present time, the role of NfL is therefore limited to a supporting clinical tool or exploratory endpoint in trials. Future developments will need to focus on the discovery of additional biomarkers for anatomically specific and other forms of nerve damage using high-throughput technologies and highly sensitive analytical platforms in adequality powered studies of appropriate design. For NfL, a better understanding of cut-off values, the relation to clinical symptoms and long-term disability as well as dynamics in serum on and off treatment is needed to further expand and proceed towards implementation.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biomarkers</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nerve damage</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Polyneuropathies</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neurofilament light chain</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Smyth, Duncan</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lunn, Michael P.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Eftimov, Filip</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Teunissen, Charlotte E.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">NeuroRX</subfield><subfield code="d">Springer-Verlag, 2006</subfield><subfield code="g">18(2021), 4 vom: Okt., Seite 2351-2367</subfield><subfield code="w">(DE-627)SPR031264964</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:18</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:4</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:2351-2367</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13311-021-01136-0</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">18</subfield><subfield code="j">2021</subfield><subfield code="e">4</subfield><subfield code="c">10</subfield><subfield code="h">2351-2367</subfield></datafield></record></collection>
|
| score |
7.3997602 |